Skip to content Skip to footer
Subscribe Now

NEWS

Transcarent to Acquire Accolade for ~$621M
Shots: Transcarent to acquire Accolade with a total equity value of ~$621M, with shareholders receiving $7.03/share in cash, making Accolade private. Closing expected in Q2’25 The acquisition will yield a unified platform with Transcarent’s WayFinding (generative AI), pharmacy benefits & overall care experiences (incl. weight health, cancer & surgery care) & Accolade’s data of…
January 9, 2025
Vividion Therapeutics to Bolster its Genomic Abilities Through the Acquisition of Tavros Therapeutics
Shots: Vividion (Bayer’s subsidiary) has acquired Tavros to strengthen its genomic capabilities via Tavros’ platform. The financial terms are undisclosed The acquisition strengthens Vividion’s functional genomics expertise by adding proprietary genomic screening approaches to discover new targets & translate the known ones. Combining resources from both the companies will enable drug discovery in oncology…
January 9, 2025
AstraZeneca and RQ Biotechnology Reports the CHMP’s Positive Opinion of Kavigale (Sipavibart) to Prevent COVID-19 in Immunocompromised Individuals
Shots: The EMA’s CHMP has granted positive opinion to Kavigale for the prevention of COVID-19 in immunocompromised individuals (≥12yrs.). It was reviewed under the EMA’s accelerated pathway Kavigale consists of an antiviral human IgG1 mAb, sipavibart, as its API that offers passive protection against SARS-CoV-2 by targeting the spike protein's receptor-binding domain Sipavibart was…
January 9, 2025
ScreenPoint Medical Reports the Acquisition of Biomediq, Bolstering its Breast Cancer Risk Evaluation Capabilities
Shots: ScreenPoint has acquired Biomediq, enhancing its breast cancer risk evaluation abilities by adding Breast AI platform, Transpara, that uses Mammographic Texture Risk biomarkers to analyze 2D & 3D mammograms & predict short & long-term risk ScreenPoint has launched Transpara 2.1, with advanced features like automated breast density evaluation (BIRADS & volumetric) & temporal…
January 9, 2025
AstraZeneca and RQ Biotechnology Reports the CHMP’s Positive Opinion of Kavigale (Sipavibart) to Prevent COVID-19 in Immunocompromised Individuals
Shots:     The EMA’s CHMP has granted positive opinion to Kavigale for the prevention of COVID-19 in immunocompromised individuals (≥12yrs.). It was reviewed under the EMA’s accelerated pathway  Kavigale consists of an antiviral human IgG1 mAb, sipavibart, as its API that offers passive protection against SARS-CoV-2 by targeting the spike protein's receptor-binding domain  Sipavibart was discovered…
January 9, 2025
J.P. Morgan Healthcare Conference Special: Dealmaker of the Year 2024 (Part 01)
Shots: The first dose of the J.P. Morgan Special: Dealmaker of the Year report based on the total number of deals signed in 2024 Last year, Roche inked 38 deals comprising acquisitions, contract services, development & commercialization, facility purchase, R&D, platform/product purchases, and sales/co-promotion Leveraging DealForma’s invaluable insights, PharmaShots brings an on-demand report…
January 8, 2025
Biocytogen Partners with Acepodia to Develop Bispecific Antibody and Dual-Payload ADCs to Treat Complex Tumors
Shots: Biocytogen & Acepodia have entered into a strategic collaboration to evaluate dual-payload bispecific antibody-drug conjugate (BsAD2C) program in complex tumors by combining the former's RenLite platform with Acepodia's Antibody-Dual-Drugs Conjugation (AD2C) tech Under the agreement, Biocytogen will provide a bispecific antibody from its RenLite platform, while Acepodia will combine 2 distinct payloads using…
January 8, 2025
Load more